ALOX15B

Across TCGA pan-cancer cohorts, ALOX15B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ALOX15B data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ALOX15B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ALOX15B expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where ALOX15B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.663	0.812	.001	44	view →
LUAD	DFS	Quartile	III,IV	0.395	0.790	.018	7	view →
LSCC	DFS	Median	II,III,IV	0.562	0.834	.019	3	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.933	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ALOX15B–PDAC (DFS)

Open the PDAC breakdown →